培美曲塞对非小细胞肺癌脑转移立体定向放疗后颅内疾病控制与放射性坏死的影响
本研究回顾149例无靶向突变的肺腺癌新发脑转移接受立体定向放疗的患者,其中105例使用培美曲塞、44例未使用。在化疗初治患者中,培美曲塞较其他方案与更低的新发脑转移风险(HR 0.42,95%CI 0.22-0.79,p=0.006)和更低的挽救性脑放疗需求(HR 0.36,95%CI 0.18-0.73,p=0.005)相关,但与影像学放射性坏死风险增加相关(HR 2.70,95%CI 1.09-6.70,p=0.03)。
要点
- 化疗初治肺腺癌脑转移立体定向放疗后使用培美曲塞可改善颅内疾病控制。
- 培美曲塞使用与影像学放射性坏死风险增加相关(HR 2.70)。
- 症状性放射性损伤是否更常见尚需进一步研究。
核心结论
- 立体定向放疗后使用培美曲塞的肺腺癌脑转移患者颅内疾病控制改善,但可能以放射性影像学坏死为代价。
研究设计与样本
- 回顾性队列研究,纳入149例无靶向突变的肺腺癌新发脑转移接受立体定向放疗的患者,其中105例使用培美曲塞、44例未使用。
- 采用Kaplan-Meier曲线和Cox回归评估培美曲塞使用与颅内疾病控制及放射性坏死的关联。
主要发现
- 在化疗初治患者中,培美曲塞组(n=43)较其他方案组(n=24)新发脑转移风险降低(HR 0.42,95%CI 0.22-0.79,p=0.006)。
- 化疗初治患者中,培美曲塞组较其他方案组挽救性脑定向放疗需求降低(HR 0.36,95%CI 0.18-0.73,p=0.005)。
- 培美曲塞使用与影像学放射性坏死风险增加相关(HR 2.70,95%CI 1.09-6.70,p=0.03)。
临床怎么用
- 对化疗初治的肺腺癌脑转移患者,立体定向放疗后使用培美曲塞可能改善颅内疾病控制并减少挽救性放疗需求。
- 使用培美曲塞期间应关注影像学放射性坏死的发生,症状性放射性损伤风险需进一步研究。
局限性
- 培美曲塞与影像学放射性坏死的关联及症状性放射性损伤是否更常见尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pemetrexed is a folate antimetabolite used in the management of advanced adenocarcinoma of the lung. We sought to assess the impact of pemetrexed on intracranial disease control and radiation-related toxicity among patients with adenocarcinoma of the lung who received stereotactic radiation for brain metastases. MATERIALS/METHODS: We identified 149 patients with adenocarcinoma of the lung and newly diagnosed brain metastases without a targetable mutation receiving stereotactic radiation. Kaplan-Meier plots and Cox regression were employed to assess whether use of pemetrexed was associated with intracranial disease control and radiation necrosis. RESULTS: Among the entire cohort, 105 patients received pemetrexed while 44 did not. Among patients who were chemotherapy-naïve, use of pemetrexed (n = 43) versus alternative regimens after stereotactic radiation (n = 24) was associated with a reduced likelihood of developing new brain metastases (HR 0.42, 95% CI 0.22-0.79, p = 0.006) and a reduced need for salvage brain-directed radiation therapy (HR 0.36, 95% CI 0.18-0.73, p = 0.005). Pemetrexed use was associated with increased radiographic necrosis. (HR 2.70, 95% CI 1.09-6.70, p = 0.03). CONCLUSIONS: Patients receiving pemetrexed after brain-directed stereotactic radiation appear to benefit from improved intracranial disease control at the possible expense of radiation-related radiographic necrosis. Whether symptomatic radiation injury occurs more frequently in patients receiving pemetrexed requires further study.
引用
- Cagney DN, Martin AM, Catalano PJ, et al. Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiother Oncol. 2018. PMID: 29398153. doi:10.1016/j.radonc.2018.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。